March 2020
Huaxipharm has signed a Letter of Intent (“LOI”) with Sirona Biochem Corp, a listed company registered under Canadian law and listed on the Toronto stock exchange Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”). Sirona has expressed their willingness to cooperate strategically with Huaxipharm. Sirona and Huaxipharm will actively explore various cooperation modes, including contract research, contract manufacturing as well as licensing, with a view to reaching an international cooperation development agreement between the two companies. The collaboration will involve on all steps to complete full commercialization of the products created by Sirona. This includes preclinical, clinical development, regulatory, commercial scale up and manufacturing for commercial applications of Sirona’s compounds for indications mutually agreed upon in the definitive agreement.
Sirona Biochem is a drug and cosmetic ingredient discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Sirona believes that its new drug discovery platform, coupled with proven success and trading flexibility, make it an excellent partner of Huaxipharm. Sirona has the ability and commitment to work with the Huaxipharm team and hopes to leverage Huaxipharm's core competencies and experience in large-scale pharmaceutical chemical synthesis and formulation to realize the common visions of Huaxipharm and Sirona in delivering novel therapies in the healthcare and cosmetics industries.
Huaxipharm is looking forward the cooperation with Sirona in the near future. For more information about Sirona, refer to its website (www.sironabiochem.com).
January 2020
Beijing Huachen United Pharmaceutical Technology Co., LTD., a holding enterprise by Huaxipharm, will to transfer part of the equity held by Huaxipharm to Zhongguancun Enterprise Development Group, a state-owned shareholder. The structure of the transaction has been determined and the transaction is under way and is expected to be completed within this year.
Huachen will further expand its business into biopharmaceutical field (diagnostic reagent, antibody) while carrying out pilot testing and industrialization projects for innovation drugs with the support of state-owned capital.
The funds returned from the equity transfer will be further used and spent for the ambitions of introducing Huaxipharm's innovative projects, as well as constructing innovation-related business segments, management teams and information systems.
December 2019
Huaxipharm and Zhongguancun Science City Innovation and Development Co., LTD. (hereinafter referred to as “Party A”) have reached a long-term consulting agreement on biomedical industry.
As a new drug research and development, consulting and service company with 17 years of experience, Huaxipharm mainly provides the following consulting services to Party A: Industry trend analysis; 2) To organize and carry out investigations (on behalf of enterprises, service institutions, the industrial parks within Zongguancun); 3) Analysis of advantages and disadvantages of development strategy (for Haidian District) and to guide and propose basic ideas for industrial development; 4) To act as the business representative of Party A at the request of Party A; 5) To provide consultation on the problems of the biomedical industry for Party A's daily work, including but not limited to the review and modification of the investigation reports, suggestions and other documentations; 6) In the name of Party A's industry consultant as instructed by Party A, to assist Party A in business discussions, and to attend important meetings or other major activities organized by Party A; 7) To provide industry consultation for the internal requirements within Party A's enterprises; Other biomedical business in daily operation of Party A.
Huaxipharm will further undertake the trust business in the biomedical and pharmaceutical areas for Zhongguancun Science City Innovation Development Co., LTD. Currently, the hosting company and the hosting team are being prepared and constructed.
November 2019
The Group of the Vice Chairmen of Lianxin Bio-Pharmaceutical Industry Alliance Visited Huachen Pharmaceutical Co., LTD., Subsidiary of Huaxipharm
Beijing Huaxipharm is a high-tech enterprise of new drug research and development. With 17 years of experience in pharmaceutical development, the company has established a sound new drug development system as well as a project incubation management system. The company possesses Huachen Pharmaceutical, Huajing Gene and other sub-brands. In the future, the company will carry out work in health diagnosis and treatment, scientific medication, health care business,and will cooperate with excellent enterprises in the industry.
Beijing Huachen is a holding enterprise by Beijing Huaxipharm, located in Beijing Daxing bio-pharmaceutical industry zone, specializing in pharmaceutical manufacturing compliant to international standards as well as in developing pharmaceutical preparation and large-scale manufacturing research. Huachen also creates an innovative drug pilot production platform for clinical trials. Huachen currently focuses on improving the industrialization incubation of innovative drugs and high-end generic drugs, and is setting up a professional team for quality control for drug listing license holders. The workshops of oral solid preparation and injection, oral liquid and nasal spray can provide production process development, technology transfer and commissioned processing services, and can also provide various forms of project equity cooperation.